## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Dennis M. Godek, et al. :

APPLICATION NO.: To Be Assigned : Examiner: Elli Peselev

(anticipated)

FILING DATE: Herewith : Group Art Unit: 1623

(anticipated)

TITLE: Azithromycin Combination for Emesis Control in:

Mammals

Mail Stop Patent Application

Hon. Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Daic. \_\_\_\_

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-4288

Respectfully submitted,

Martha G. Munchhof

Attorney for Applicant(s)

Reg. No. 47,811

INFORMATION DISCLOSURE CITATION							ATTY. DOCKET NO. PC9940D					SERIAL NO. To Assigned			Ве		
(Use several sheets if necessary)							APPLICANT Dennis M. Godek, et al.										
·							FILING DATE Herewith					OUP cipated)	1623				
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL				DOCI	UMENT NUM	BER			DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	US	5	9	0	0	2	5	7	5/5/99	Breton, et a	2	424	639				
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER									DATE	COUNTRY		CLASS	SUBCLASS	TRANS			
	<del></del>		Γ				Ţ	T					<del> </del>	YES	NO		
<b> </b>	EP	0	3	0	7	1_	2	8	8/31/88	EPO		A61K	31/71				
	EP	0	6	2	7	2	2	1	5/16/94	EPO		A61K	31/435				
	EP	0	7	7	3	0	2	6	11/6/96	EPO		A61K	31/445				
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																
	T	T															
	$\bot$		Longmore, et al., "Neuokinin-receptor antagonists: pharmacological tools and therapeutic drugs", <u>Can. J. Physiol. Pharmacol.</u> 75, pp. 612-621 (1997)														
			Quartara, et al., "The tachykinin NK, receptor. Part II: distribution and pathophysiological roles", Neuropeptides 32(1), pp. 1-49 (1998)														
			Rosen, et al., "Synthesis and Structure-Activity Relationships of CP-122,721, a second-generation NK-1 Receptor Antagonist", Bioorganic & Medicinal Chemistry Letters 8, pp. 281-284 (1998)														
			Gardner, et al., "The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK <sub>1</sub> receptor antagonist GR 203040", Br. Journal of Pharmacology 116, pp. 3158-3163 (1995)														
			Quin Sin Yu, et al., PREV199395089139 BIOSIS 1993 (XP-002196779)														
			<u> </u>	<u>a., , , , , , , , , , , , , , , , , , , </u>	1000000	<u> </u>	10010 100										
EXAMINE	R							DATE C	CONSIDERE	D							
EXAMINER: next commun			sidered, wha	ether or not cit	tation is in co	informance	with MPEP 6	09; Draw line	through citation	if not in conformance	and not c	onsidered. In	clude copy of th	is form w	ith		

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE